Safety data sheet. GHS / OSHA HCS 2012 format, 16 sections. Issued by Epic Peptides Lab for the catalogue items listed in Section 1.

Epic Peptides Lab

Safety data sheet · capsules

Epic Peptides Lab · USA

Document number: PL-SDS-164
Revision: 1.0 · 2026-10-03

Tesofensine

capsules

1Identification

Product Identifier

Tesofensine

Document Number

PL-SDS-164

Catalogue Items Covered

Id
5089
Name
Tesofensine 500mcg (30 Capsules)
Sku
PL-TESO-500MCG-CAP

Recommended Use

Laboratory research use by trained personnel.

Restrictions On Use

Not for human or veterinary use.

Supplier / Distributor

Epic Peptides Lab, USA

Telephone

+1 (787) 468-5291

info@epicpeptideslab.com

2Hazard(s) identification

Classification: Not classified as hazardous under OSHA HCS 2012 (29 CFR 1910.1200) or UN GHS, on the basis of the supplier safety data sheets consulted.
Label Elements: No data available.
Signal Word: No data available.
Other Hazards: No data available.

3Composition / information on ingredients

Description

Hard gelatin capsules containing the active substance blended with microcrystalline cellulose, packed in a sealed bottle.

Composition

Name
Tesofensine
Full
Tesofensine (NS-2330), phenyltropane; small molecule
Cas
195875-84-4
Formula
C17H23Cl2NO
Conc
as labelled
Qty
as labelled
Name
Microcrystalline cellulose
Full
Microcrystalline cellulose (capsule filler)
Cas
9004-34-6
Formula
(C6H10O5)n
Conc
balance of capsule contents
Name
Gelatin
Full
Gelatin (capsule shell)
Cas
9000-70-8
Conc
capsule shell

4First-aid measures

First Aid Measures

Inhalation: Move the person to fresh air and keep comfortable for breathing. If breathing is difficult or symptoms persist, call a POISON CENTER or doctor.
Skin: Take off contaminated clothing. Wash the skin with plenty of soap and water. If irritation or a rash develops, get medical advice.
Eyes: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice.
Ingestion: Rinse mouth. Do not induce vomiting. Call a POISON CENTER or doctor if you feel unwell.

Most Important Symptoms And Effects

No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

Likely Routes Of Exposure

Ingestion; inhalation of dust and skin/eye contact if capsules are opened.

5Fire-fighting measures

Fire Fighting Information: Combustible organic solid; capsule contents may form combustible dust if dispersed in bulk.

6Accidental release measures

Spill And Clean Up Procedures: Collect intact capsules. Dampen any spilled powder with water, wipe up with absorbent material and place in a sealed container for disposal.

7Handling and storage

Safe Handling: Do not open or crush capsules unless required for an experiment; if capsule contents are handled as a powder, avoid generating dust and weigh inside a ventilated enclosure. Wash hands after handling.
Safe Storage: Store at room temperature (15–25 °C) in the tightly closed original container, dry and protected from light.
Storage Temperature: 15–25 °C, dry, protected from light
Incompatible Materials: Strong oxidizing agents; strong acids (amine) (generic).

8Exposure controls / personal protection

Occupational Exposure Limits: Microcrystalline cellulose: OSHA PEL 15 mg/m³ (total dust), 5 mg/m³ (respirable fraction); ACGIH TLV 10 mg/m³ (as cellulose).

No occupational exposure limits have been established for the active ingredient(s).
Exposure Controls And PPE: No data available.

9Physical and chemical properties

Physical State

Solid

Appearance

Hard gelatin capsules containing a white to off-white powder

Properties

Odor: Characteristic (Cayman)
Ph: Not applicable (solid)
Melting: Undetermined (Cayman)
Boiling: Undetermined (Cayman)
Flash: Not applicable (non-flammable solid); combustible organic material
Vapour: Negligible (solid)
Density: No data available (bulk density of lyophilized cake is low)
Solubility: DMF 2 mg/mL; DMSO 1 mg/mL; ethanol slightly soluble; PBS (pH 7.2) 0.14 mg/mL (Cayman)
Logp: Not in SDS (lipophilic tertiary amine, predicted logP ~4)
Decomp: No data available; peptides decompose above about 200 °C
Other: (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane (NS 2330), phenyltropane, C17H23Cl2NO, MW 328.3, CAS 195875-84-4; relative density 1.161 g/cm3 (predicted, Targ.

10Stability and reactivity

Stability And Reactivity

Reactivity: No dangerous reactions known (Cayman).
Incompatible: Strong oxidizing agents; strong acids (amine) (generic).
Decomposition: No dangerous decomposition products known (Cayman); combustion gives carbon oxides, nitrogen oxides, hydrogen chloride.
Conditions To Avoid: Heat, light, moisture.

Conditions To Avoid

Heat, light, moisture

Incompatible Materials

No data available.

11Toxicological information

Toxicological Information: Acute toxicity, oral
No data available

Acute toxicity, dermal
No data available

Acute toxicity, inhalation
No data available

Skin corrosion/irritation
No irritant effect (Cayman)

Serious eye damage/irritation
No irritating effect (Cayman)

Respiratory or skin sensitisation
No sensitizing effects known (Cayman)

Germ cell mutagenicity
No data available

Carcinogenicity
Not listed by IARC, NTP or OSHA-Ca (Cayman)

Reproductive toxicity
No data available

STOT, single exposure
No data available

STOT, repeated exposure
No data available

Aspiration hazard
No data available
Routes Of Exposure: Ingestion; inhalation of dust and skin/eye contact if capsules are opened.
Symptoms: No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

12Ecological information

Ecological Information: Cayman: Water hazard class 1 (self-assessment): slightly hazardous for water; do not allow undiluted product or large quantities to reach ground water, water course or sewage system. No ecotoxicity test data available. Lipophilic dichlorophenyl amine - potential for bioaccumulation; no aquatic data.

13Disposal considerations

Disposal Guidance: No data available.

14Transport information

Transport Classification

Note: Not regulated as a dangerous good for transport by road (DOT 49 CFR), air (IATA/ICAO) or sea (IMDG). Not a marine pollutant. Ship refrigerated or frozen as required by Section 7; the coolant (dry ice, UN 1845) is regulated when used.

15Regulatory information

Regulatory Information

Tsca: Not listed on TSCA inventory (Cayman). R&D exemption applies.
Carcinogen Listings: Not listed by IARC, NTP, OSHA, California Prop 65.
Dea: Not a US DEA-scheduled substance (verify at time of issue; it is a phenyltropane monoamine reuptake inhibitor, structurally related to controlled cocaine analogues but not itself listed).
Other: Not FDA-approved (investigational anti-obesity drug; marketed in Mexico after 2023 approval). WADA remark: not explicitly named; monoamine reuptake inhibitors with stimulant effects may fall under S6 (stimulants, in-competition) 'similar biological effect' language - remark only.

Carcinogen Listings

No data available.

16Other information

Revision: October 3, 2026
Sources Consulted: Cayman Chemical

TargetMol

MedChemExpress

Spectrum Chemical

Sigachi Industries

Parchem

Fisher Scientific / Acros Organics

Electron Microscopy Sciences
Confidence: medium
Additional Information: Potent triple monoamine reuptake inhibitor active at sub-milligram doses; handle as a potent pharmacological agent.

Back to SDS list